HAMP and chronic kidney disease: A previous study conducted to study the safety of higher doses of daprodustat with 10 and 25 mg doses, in HD-CKD and NDD-CKD patients previously receiving rhEPO therapy, showed a significant dose-dependent increase in Hgb levels, and there was a decrease in the hepcidin level; however, 50% of the subjects withdrew from the 25-mg dose after 2 weeks due to a significant increase in Hgb levels more than 1 g/dL (56).